Back to results
US 2026/0308807 A1Published application
Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
AssigneeZhejiang Nanomab Technology Center Co. Ltd.
InventorWeimin ZHU
Life of this patent
Estimating the term…
Abstract
A method for generating a plurality of diverse camelid antibodies to cover functional epitopes of the target with high-resolution. Also provided is a method for generating camelid antibodies.
Claims10
1-8. (canceled)
A method generating a camelid antibody specific for an antigen, comprising:
- a) enriching and proliferating B-cells from immunized camelids specific to the antigen,
- b) generating antibody NGS libraries comprising VHH2, VHH3, VH1 and VL1 chain sequences from said antigen-specific B-cells,
- c) grouping sequences of VHH2, VHH3, VH1 and VL1 in the NGS libraries by lineages,
- d) pairing VH1/VL1 lineage according to anchor binders generated by single B-cell sorting and heterohybridoma approaches,
- e) subgrouping the lineages and lineage pairs in step d), respectively, by VHH unique features selected from a group consisting of
- i. FR2 hydrophilic region,
- ii. extended CDR1,
- iii. extra disulfide bond between CDR1-CDR3 or FR2-CDR3,
- iv. extra disulfide bond within CDR3,
- v. long CDR3 (12 amino acids or more),
- vi. extra disulfide bond within CDR1,
- vii. non-classic VHH which have the same V and J germlines as conventional IgG1,
- viii. non-classic VHH which have predetermined sequence signatures,
- ix. predetermined novel canonical binding loop structure,
- x. convergent motif or sequence signature,
- xi. long CDR2 (14-17 amino acids);
- xii. absence of 3 or more continuing positive charges in CDR3;
- xiii. absence of positive charge at N-terminus;
- xiv. even number of cysteines in the sequence;
- and
- xv. 2-4 amino acid motifs in the CDR regions, wherein the motif is identified from the 3D structures of a ligand/receptor complex;
- f) ranking lineages and lineage pairs from step c) and step d) by one or more lineage priority factors,
- g) selecting a representative sequence or sequence pair from a lineage of VHH2 or VHH3 and a lineage pair of VH1/VL1 respectively with a top ranking from step f) in the NGS library,
- h) testing an antibody comprising the selected sequence pair or sequence from step
- g) to determine if the antibody binds to the antigen or portion thereof.
22 more elements
16-24. (canceled)
Dependencies are inferred from the claim text.